{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:09:50Z","timestamp":1789873790411,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["CASE award (Pfizer)"],"award-info":[{"award-number":["CASE award (Pfizer)"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13071-016-1381-0","type":"journal-article","created":{"date-parts":[[2016,2,20]],"date-time":"2016-02-20T02:44:31Z","timestamp":1455936271000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["The TLR2\/6 ligand PAM2CSK4 is a Th2 polarizing adjuvant in Leishmania major and Brugia malayi murine vaccine models"],"prefix":"10.1186","volume":"9","author":[{"given":"Alice","family":"Halliday","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,20]]},"reference":[{"issue":"1","key":"1381_CR1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1600-065X.2010.00978.x","volume":"239","author":"MS Duthie","year":"2011","unstructured":"Duthie MS et al. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev. 2011;239(1):178\u201396.","journal-title":"Immunol Rev"},{"issue":"10","key":"1381_CR2","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","volume":"183","author":"AM Didierlaurent","year":"2009","unstructured":"Didierlaurent AM et al. AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity. J Immunol. 2009;183(10):6186\u201397.","journal-title":"J Immunol"},{"issue":"34","key":"1381_CR3","doi-asserted-by":"crossref","first-page":"12294","DOI":"10.1073\/pnas.1400478111","volume":"111","author":"C Maisonneuve","year":"2014","unstructured":"Maisonneuve C et al. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci U S A. 2014;111(34):12294\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1381_CR4","doi-asserted-by":"crossref","unstructured":"Raman VS, et al. Adjuvants for Leishmania vaccines: From Models to Clinical Application. Front Immunol. 2012;3:144:1-15.","DOI":"10.3389\/fimmu.2012.00144"},{"issue":"46","key":"1381_CR5","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1016\/j.vaccine.2010.08.092","volume":"28","author":"A Llanos-Cuentas","year":"2010","unstructured":"Llanos-Cuentas A et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1\u2009+\u2009MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine. 2010;28(46):7427\u201335.","journal-title":"Vaccine"},{"issue":"2","key":"1381_CR6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1586\/14760584.2.2.239","volume":"2","author":"SG Reed","year":"2003","unstructured":"Reed SG, Coler RN, Campos-Neto A. Development of a leishmaniasis vaccine: the importance of MPL. Expert Rev Vaccines. 2003;2(2):239\u201352.","journal-title":"Expert Rev Vaccines"},{"issue":"12","key":"1381_CR7","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1084\/jem.20020147","volume":"195","author":"EG Rhee","year":"2002","unstructured":"Rhee EG et al. Vaccination with Heat-killed Leishmania Antigen or Recombinant Leishmanial Protein and CpG Oligodeoxynucleotides Induces Long-Term Memory CD4\u2009+\u2009and CD8\u2009+\u2009T Cell Responses and Protection Against Leishmania major Infection. J Exp Med. 2002;195(12):1565\u201373.","journal-title":"J Exp Med"},{"issue":"10","key":"1381_CR8","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.4049\/jimmunol.1201676","volume":"189","author":"NC Peters","year":"2012","unstructured":"Peters NC et al. Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL\/6 mice. J Immunol. 2012;189(10):4832\u201341.","journal-title":"J Immunol"},{"issue":"2","key":"1381_CR9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0166-6851(03)00160-9","volume":"130","author":"I Becker","year":"2003","unstructured":"Becker I et al. Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2. Mol Biochem Parasitol. 2003;130(2):65\u201374.","journal-title":"Mol Biochem Parasitol"},{"issue":"10","key":"1381_CR10","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1017\/S0031182009990473","volume":"136","author":"G Kavoosi","year":"2009","unstructured":"Kavoosi G, Ardestani SK, Kariminia A. The involvement of TLR2 in cytokine and reactive oxygen species (ROS) production by PBMCs in response to Leishmania major phosphoglycans (PGs). Parasitology. 2009;136(10):1193\u20139.","journal-title":"Parasitology"},{"issue":"7","key":"1381_CR11","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1128\/IAI.00154-09","volume":"77","author":"DA Vargas-Inchaustegui","year":"2009","unstructured":"Vargas-Inchaustegui DA et al. Distinct Roles for MyD88 and Toll-Like Receptor 2 during Leishmania braziliensis Infection in Mice. Infect Immun. 2009;77(7):2948\u201356.","journal-title":"Infect Immun"},{"issue":"12","key":"1381_CR12","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.1073\/pnas.96.12.6970","volume":"96","author":"PS Walker","year":"1999","unstructured":"Walker PS et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci U S A. 1999;96(12):6970\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1381_CR13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.imlet.2005.12.002","volume":"105","author":"MX Hern\u00e1ndez","year":"2006","unstructured":"Hern\u00e1ndez MX et al. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12\/23p40. Immunol Lett. 2006;105(1):38\u201347.","journal-title":"Immunol Lett"},{"issue":"10","key":"1381_CR14","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.4049\/jimmunol.1201676","volume":"189","author":"NC Peters","year":"2012","unstructured":"Peters NC, et al. Evaluation of Recombinant Leishmania Polyprotein Plus Glucopyranosyl Lipid A Stable Emulsion Vaccines against Sand Fly-Transmitted Leishmania major in C57BL\/6 Mice. J Immunol. 2012;189(10):4832\u201341.","journal-title":"J Immunol"},{"issue":"33","key":"1381_CR15","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.1016\/j.vaccine.2010.05.077","volume":"28","author":"I Okwor","year":"2010","unstructured":"Okwor I, Kuriakose S, Uzonna J. Repeated inoculation of killed Leishmania major induces durable immune response that protects mice against virulent challenge. Vaccine. 2010;28(33):5451\u20137.","journal-title":"Vaccine"},{"issue":"8","key":"1381_CR16","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1086\/501351","volume":"42","author":"JD Turner","year":"2006","unstructured":"Turner JD et al. A Randomized, Double\u2010Blind Clinical Trial of a 3\u2010Week Course of Doxycycline plus Albendazole and Ivermectin for the Treatment of Wuchereria bancrofti Infection. Clin Infect Dis. 2006;42(8):1081\u20139.","journal-title":"Clin Infect Dis"},{"issue":"33","key":"1381_CR17","doi-asserted-by":"crossref","first-page":"22364","DOI":"10.1074\/jbc.M901528200","volume":"284","author":"JD Turner","year":"2009","unstructured":"Turner JD et al. Wolbachia Lipoprotein Stimulates Innate and Adaptive Immunity through Toll-like Receptors 2 and 6 to Induce Disease Manifestations of Filariasis. J Biol Chem. 2009;284(33):22364\u201378.","journal-title":"J Biol Chem"},{"issue":"5","key":"1381_CR18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-3024.2011.01350.x","volume":"34","author":"SA Babayan","year":"2012","unstructured":"Babayan SA, Allen JE, Taylor DW. Future prospects and challenges of vaccines against filariasis. Parasite Immunol. 2012;34(5):243\u201353.","journal-title":"Parasite Immunol"},{"issue":"8","key":"1381_CR19","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.ijpara.2006.04.013","volume":"36","author":"SA Babayan","year":"2006","unstructured":"Babayan SA et al. Vaccination against filarial nematodes with irradiated larvae provides long-term protection against the third larval stage but not against subsequent life cycle stages. Int J Parasitol. 2006;36(8):903\u201314.","journal-title":"Int J Parasitol"},{"issue":"4","key":"1381_CR20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0014-4894(02)00015-2","volume":"100","author":"TV Rajan","year":"2002","unstructured":"Rajan TV et al. Brugian infections in the peritoneal cavities of laboratory mice: kinetics of infection and cellular responses. Exp Parasitol. 2002;100(4):235\u201347.","journal-title":"Exp Parasitol"},{"issue":"3","key":"1381_CR21","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1128\/IAI.71.3.1370-1378.2003","volume":"71","author":"N Paciorkowski","year":"2003","unstructured":"Paciorkowski N, Shultz LD, Rajan TV. Primed peritoneal B lymphocytes are sufficient to transfer protection against Brugia pahangi infection in mice. Infect Immun. 2003;71(3):1370\u20138.","journal-title":"Infect Immun"},{"issue":"2","key":"1381_CR22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/PL00008258","volume":"189","author":"C Martin","year":"2000","unstructured":"Martin C et al. IL-5 is essential for vaccine-induced protection and for resolution of primary infection in murine filariasis. Med Microbiol Immunol. 2000;189(2):67\u201374.","journal-title":"Med Microbiol Immunol"},{"issue":"5","key":"1381_CR23","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/eji.1830270528","volume":"27","author":"L Benmohamed","year":"1997","unstructured":"Benmohamed L et al. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur J Immunol. 1997;27(5):1242\u201353.","journal-title":"Eur J Immunol"},{"issue":"7","key":"1381_CR24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1473-3099(02)00318-3","volume":"2","author":"L BenMohamed","year":"2002","unstructured":"BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines--yesterday, today, and tomorrow. Lancet Infect Dis. 2002;2(7):425\u201331.","journal-title":"Lancet Infect Dis"},{"issue":"43","key":"1381_CR25","doi-asserted-by":"crossref","first-page":"15440","DOI":"10.1073\/pnas.0406740101","volume":"101","author":"DC Jackson","year":"2004","unstructured":"Jackson DC et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A. 2004;101(43):15440\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"1381_CR26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-3024.1994.tb00364.x","volume":"16","author":"AJ Bancroft","year":"1994","unstructured":"Bancroft AJ et al. The role of CD4 cells in protective immunity to Brugia pahangi. Parasite Immunol. 1994;16(7):385\u20137.","journal-title":"Parasite Immunol"},{"issue":"1","key":"1381_CR27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1574-6968.1993.tb06003.x","volume":"107","author":"PA Bates","year":"1993","unstructured":"Bates PA. Characterization of developmentally-regulated nucleases in promastigotes and amastigotes of Leishmania mexicana. FEMS Microbiol Lett. 1993;107(1):53\u20138.","journal-title":"FEMS Microbiol Lett"},{"issue":"5","key":"1381_CR28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/laban0510-143","volume":"39","author":"KG Griffiths","year":"2010","unstructured":"Griffiths KG et al. Using an intravenous catheter to carry out abdominal lavage in the gerbil. Lab Anim (NY). 2010;39(5):143\u20138.","journal-title":"Lab Anim (NY)"},{"issue":"5","key":"1381_CR29","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0738-081X(96)00071-5","volume":"14","author":"K Bahar","year":"1996","unstructured":"Bahar K et al. Comparative safety and immunogenicity trial of two killed Leishmania Major vaccines with or without BCG in human volunteers. Clin Dermatol. 1996;14(5):489\u201395.","journal-title":"Clin Dermatol"},{"issue":"2","key":"1381_CR30","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.4049\/jimmunol.177.2.1240","volume":"177","author":"JD Turner","year":"2006","unstructured":"Turner JD et al. Wolbachia Endosymbiotic Bacteria of Brugia malayi Mediate Macrophage Tolerance to TLR- and CD40-Specific Stimuli in a MyD88\/TLR2-Dependent Manner. J Immunol. 2006;177(2):1240\u20139.","journal-title":"J Immunol"},{"key":"1381_CR31","doi-asserted-by":"crossref","unstructured":"Finkelman FD et al. Lymphokine Control of in vivo Immunoglobulin Isotype Selection. Annu Rev Immunol. 1990;8(1):303\u201333.","DOI":"10.1146\/annurev.iy.08.040190.001511"},{"issue":"5","key":"1381_CR32","doi-asserted-by":"crossref","first-page":"506","DOI":"10.2174\/092986708783503249","volume":"15","author":"PM Moyle","year":"2008","unstructured":"Moyle PM, Toth I. Self-adjuvanting lipopeptide vaccines. Curr Med Chem. 2008;15(5):506\u201316.","journal-title":"Curr Med Chem"},{"key":"1381_CR33","doi-asserted-by":"crossref","unstructured":"Zaman M, Toth I. Immunostimulation by synthetic lipopeptide based vaccine candidates: structureactivity relationships. Front Immunol 2013;4:318:1-12.","DOI":"10.3389\/fimmu.2013.00318"},{"issue":"4","key":"1381_CR34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/icb.2013.102","volume":"92","author":"BY Chua","year":"2014","unstructured":"Chua BY et al. The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T-cell responses. Immunol Cell Biol. 2014;92(4):377\u201383.","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"1381_CR35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1128\/IAI.70.1.240-248.2002","volume":"70","author":"J Cote-Sierra","year":"2002","unstructured":"Cote-Sierra J et al. Bacterial Lipoprotein-Based Vaccines Induce Tumor Necrosis Factor-Dependent Type 1 Protective Immunity against Leishmania major. Infect Immun. 2002;70(1):240\u20138.","journal-title":"Infect Immun"},{"issue":"5","key":"1381_CR36","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1084\/jem.20041470","volume":"201","author":"SA Miles","year":"2005","unstructured":"Miles SA et al. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med. 2005;201(5):747\u201354.","journal-title":"J Exp Med"},{"issue":"6","key":"1381_CR37","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.191.6.1063","volume":"191","author":"PE Kima","year":"2000","unstructured":"Kima PE et al. Internalization of Leishmania mexicana Complex Amastigotes via the Fc Receptor Is Required to Sustain Infection in Murine Cutaneous Leishmaniasis. J Exp Med. 2000;191(6):1063\u20138.","journal-title":"J Exp Med"},{"issue":"2","key":"1381_CR38","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1128\/IAI.00316-07","volume":"76","author":"BN Thomas","year":"2008","unstructured":"Thomas BN, Buxbaum LU. Fc{gamma}RIII Mediates Immunoglobulin G-Induced Interleukin-10 and Is Required for Chronic Leishmania mexicana Lesions. Infect Immun. 2008;76(2):623\u201331.","journal-title":"Infect Immun"},{"issue":"4","key":"1381_CR39","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1128\/IAI.73.4.2101-2108.2005","volume":"73","author":"LU Buxbaum","year":"2005","unstructured":"Buxbaum LU, Scott P. Interleukin 10- and Fc\u03b3 Receptor-Deficient Mice Resolve Leishmania mexicana Lesions. Infect Immun. 2005;73(4):2101\u20138.","journal-title":"Infect Immun"},{"issue":"4","key":"1381_CR40","doi-asserted-by":"crossref","first-page":"e18833","DOI":"10.1371\/journal.pone.0018833","volume":"6","author":"S Yamazaki","year":"2011","unstructured":"Yamazaki S et al. TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS One. 2011;6(4):e18833.","journal-title":"PLoS One"},{"issue":"9","key":"1381_CR41","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.4049\/jimmunol.169.9.4905","volume":"169","author":"W Zeng","year":"2002","unstructured":"Zeng W et al. Highly Immunogenic and Totally Synthetic Lipopeptides as Self-Adjuvanting Immunocontraceptive Vaccines. J Immunol. 2002;169(9):4905\u201312.","journal-title":"J Immunol"},{"issue":"3","key":"1381_CR42","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1096\/fj.11-184556","volume":"26","author":"S Hutchison","year":"2012","unstructured":"Hutchison S et al. Antigen depot is not required for alum adjuvanticity. FASEB J. 2012;26(3):1272\u20139.","journal-title":"FASEB J"},{"issue":"5807","key":"1381_CR43","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1126\/science.1135299","volume":"314","author":"AL Gavin","year":"2006","unstructured":"Gavin AL et al. Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor Signaling. Science. 2006;314(5807):1936\u20138.","journal-title":"Science"},{"issue":"14","key":"1381_CR44","doi-asserted-by":"crossref","first-page":"9049","DOI":"10.1074\/jbc.M512525200","volume":"281","author":"U Buwitt-Beckmann","year":"2006","unstructured":"Buwitt-Beckmann U et al. TLR1- and TLR6-independent Recognition of Bacterial Lipopeptides. J Biol Chem. 2006;281(14):9049\u201357.","journal-title":"J Biol Chem"},{"issue":"7198","key":"1381_CR45","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature06939","volume":"453","author":"SC Eisenbarth","year":"2008","unstructured":"Eisenbarth SC et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453(7198):1122\u20136.","journal-title":"Nature"},{"issue":"4","key":"1381_CR46","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","volume":"33","author":"RL Coffman","year":"2010","unstructured":"Coffman RL, Sher A, Seder RA. Vaccine Adjuvants: Putting Innate Immunity to Work. Immunity. 2010;33(4):492\u2013503.","journal-title":"Immunity"},{"issue":"5","key":"1381_CR47","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.immuni.2007.11.003","volume":"27","author":"AS McKee","year":"2007","unstructured":"McKee AS, Munks MW, Marrack P. How Do Adjuvants Work? Important Considerations for New Generation Adjuvants. Immunity. 2007;27(5):687\u201390.","journal-title":"Immunity"},{"issue":"4","key":"1381_CR48","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nm.2306","volume":"17","author":"TL Flach","year":"2011","unstructured":"Flach TL et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med. 2011;17(4):479\u201387.","journal-title":"Nat Med"},{"issue":"4","key":"1381_CR49","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/1521-4141(200204)32:4<1114::AID-IMMU1114>3.0.CO;2-B","volume":"32","author":"CA Gray","year":"2002","unstructured":"Gray CA, Lawrence RA. A role for antibody and Fc receptor in the clearance of Brugia malayi microfilariae. Eur J Immunol. 2002;32(4):1114\u201320.","journal-title":"Eur J Immunol"},{"issue":"11","key":"1381_CR50","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.1128\/IAI.69.11.7067-7073.2001","volume":"69","author":"C Martin","year":"2001","unstructured":"Martin C et al. B-cell deficiency suppresses vaccine-induced protection against murine filariasis but does not increase the recovery rate for primary infection. Infect Immun. 2001;69(11):7067\u201373.","journal-title":"Infect Immun"},{"issue":"7-8","key":"1381_CR51","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/pim.12034","volume":"35","author":"S Sharmila","year":"2013","unstructured":"Sharmila S et al. Bacterial lipid modification enhances immunoprophylaxis of filarial abundant larval transcript-2 protein in Mastomys model. Parasite Immunol. 2013;35(7-8):201\u201313.","journal-title":"Parasite Immunol"},{"issue":"8","key":"1381_CR52","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.4049\/jimmunol.172.8.4733","volume":"172","author":"S Dillon","year":"2004","unstructured":"Dillon S et al. A Toll-Like Receptor 2 Ligand Stimulates Th2 Responses In Vivo, via Induction of Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase and c-Fos in Dendritic Cells. J Immunol. 2004;172(8):4733\u201343.","journal-title":"J Immunol"},{"issue":"4","key":"1381_CR53","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1172\/JCI27203","volume":"116","author":"S Dillon","year":"2006","unstructured":"Dillon S et al. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J Clin Invest. 2006;116(4):916\u201328.","journal-title":"J Clin Invest"},{"issue":"9","key":"1381_CR54","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/infdis\/jir548","volume":"204","author":"U Gowthaman","year":"2011","unstructured":"Gowthaman U et al. Promiscuous peptide of 16\u00a0kDa antigen linked to Pam2Cys protects against Mycobacterium tuberculosis by evoking enduring memory T-cell response. J Infect Dis. 2011;204(9):1328\u201338.","journal-title":"J Infect Dis"},{"issue":"7","key":"1381_CR55","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.4049\/jimmunol.1400672","volume":"193","author":"SP Pandey","year":"2014","unstructured":"Pandey SP et al. Pegylated Bisacycloxypropylcysteine, a Diacylated Lipopeptide Ligand of TLR6, Plays a Host-Protective Role against Experimental Leishmania major Infection. J Immunol. 2014;193(7):3632\u201343.","journal-title":"J Immunol"},{"issue":"6","key":"1381_CR56","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1371\/journal.pntd.0001204","volume":"5","author":"A Jayakumar","year":"2011","unstructured":"Jayakumar A et al. TLR1\/2 Activation during Heterologous Prime-Boost Vaccination (DNA-MVA) Enhances CD8+ T Cell Responses Providing Protection against Leishmania (Viannia). PLoS Negl Trop Dis. 2011;5(6):e1204.","journal-title":"PLoS Negl Trop Dis"},{"key":"1381_CR57","doi-asserted-by":"crossref","unstructured":"Awate S, Babiuk LA, and Mutwiri G. Mechanisms of action of adjuvants. Front Immunol 2013;4:114:1-10.","DOI":"10.3389\/fimmu.2013.00114"},{"issue":"6","key":"1381_CR58","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","volume":"12","author":"B Pulendran","year":"2011","unstructured":"Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;12(6):509\u201317.","journal-title":"Nat Immunol"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-016-1381-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T16:25:58Z","timestamp":1567614358000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.parasitesandvectors.com\/content\/9\/1\/96"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,20]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1381"],"URL":"https:\/\/doi.org\/10.1186\/s13071-016-1381-0","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,20]]},"article-number":"96"}}